Evidence map›Paper›PMID 29659623›Full record

ArticlePLoS pathogens2018

Loss of CXCR6 coreceptor usage characterizes pathogenic lentiviruses.

Katherine S Wetzel, Yanjie Yi, Anjana Yadav, Anya M Bauer, Ezekiel A Bello, Dino C Romero, Frederic Bibollet-Ruche, Beatrice H Hahn, Mirko Paiardini, Guido Silvestri and 2 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. CD4 receptor diversity represents an ancient protection mechanism against primate lentiviruses.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Katherine S WetzelDepartments of Medicine and Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States of America.
Yanjie YiDepartments of Medicine and Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States of America.
Anjana YadavDepartments of Medicine and Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States of America.ORCID 0000-0003-0818-963X
Anya M BauerDepartments of Medicine and Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States of America.
Ezekiel A BelloDepartments of Medicine and Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States of America.ORCID 0000-0001-9546-8180
Dino C RomeroDepartments of Medicine and Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States of America.ORCID 0000-0001-7230-0908
Frederic Bibollet-RucheDepartments of Medicine and Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States of America.
Beatrice H HahnDepartments of Medicine and Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States of America.
Mirko PaiardiniDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Atlanta, GA, United States of America.
Guido SilvestriDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Atlanta, GA, United States of America.
Martine PeetersUMI233-TransVIHMI/INSERM U1175, Institut de Recherche pour le Développement (IRD) and University of Montpellier, Montpellier, France.
Ronald G CollmanDepartments of Medicine and Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States of America.
University of Pennsylvania · USEmory National Primate Research CenterInserm · FR

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROBERT GROSS · 1999 to 2026
$78.6M
TRAINING IN HIV PATHOGENESIST32AI007632 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Frederic D Bushman, James L. Riley · 2000 to 2026
$10.6M
STUDIES OF NATURAL SIV INFECTION OF SOOTY MANGABEYSR37AI066998 · NIAID · EMORY UNIVERSITY · PI SILVESTRI, GUIDO · 2011 to 2020
$7.7M
Natural SIV Reservoirs and Human Zoonotic RiskR37AI050529 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2008 to 2017
$5.7M
Studies of the precursor of the human AIDS virus in its natural chimpanzee hostR01AI120810 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HAHN, BEATRICE H · 2016 to 2020
$3.4M
Entry Coreceptor Use & Target Cell Tropism in Nonpathogenic SIV InfectionR56AI091516 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI COLLMAN, RONALD G · 2011 to 2011
$449k
NIAID NIH HHS P30 AI045008NIAID NIH HHS R01 AI120810NIAID NIH HHS R37 AI050529NIAID NIH HHS R37 AI066998NIAID NIH HHS R56 AI091516NIAID NIH HHS T32 AI007632NIH HHS P30-AI045008NIH HHS P51 OD011132NIH HHS R01-AI120810NIH HHS R01-MH061130NIH HHS R37-AI050529NIH HHS R37-AI66998NIH HHS R56-AI091516
6 · The paper itself

Abstract

Pandemic HIV-1 originated from the cross-species transmission of SIVcpz, which infects chimpanzees, while SIVcpz itself emerged following the cross-species transmission and recombination of monkey SIVs, with env contributed by the SIVgsn/mus/mon lineage that infects greater spot-nosed, mustached and mona monkeys. SIVcpz and HIV-1 are pathogenic in their respective hosts, while the phenotype of their SIVgsn/mus/mon ancestors is unknown. However, two well-studied SIV infected natural hosts, sooty mangabeys (SMs) and African green monkeys (AGMs), typically remain healthy despite high viral loads; these species express low levels of the canonical coreceptor CCR5, and recent work shows that CXCR6 is a major coreceptor for SIV in these hosts. It is not known what coreceptors were used by the precursors of SIVcpz, whether coreceptor use changed during emergence of the SIVcpz/HIV-1 lineage, and what T cell subsets express CXCR6 in natural hosts. Using species-matched coreceptors and CD4, we show here that SIVcpz uses only CCR5 for entry and, like HIV-1, cannot use CXCR6. In contrast, SIVmus efficiently uses both CXCR6 and CCR5. Coreceptor selectivity was determined by Env, with CXCR6 use abrogated by Pro326 in the V3 crown, which is absent in monkey SIVs but highly conserved in SIVcpz/HIV-1. To characterize which cells express CXCR6, we generated a novel antibody that recognizes CXCR6 of multiple primate species. Testing lymphocytes from SM, the best-studied natural host, we found that CXCR6 is restricted to CD4+ effector memory cells, and is expressed by a sub-population distinct from those expressing CCR5. Thus, efficient CXCR6 use, previously identified in SM and AGM infection, also characterizes a member of the SIV lineage that gave rise to SIVcpz/HIV-1. Loss of CXCR6 usage by SIVcpz may have altered its cell tropism, shifting virus from CXCR6-expressing cells that may support replication without disrupting immune function or homeostasis, towards CCR5-expressing cells with pathogenic consequences.

Indexed as

Viral LoadAmino Acid SequenceAnimalsCD4-Positive T-LymphocytesCercocebus atysMacaca mulattaPhylogenyReceptors, CCR5Receptors, CXCR6Sequence HomologySimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusVirus InternalizationReceptors, CCR5Receptors, CXCR6

Identifiers

PMID29659623
PMCPMC5919676
OpenAlexW2802550999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.